Temporomandibular Dysfunction in Patients With Tinnitus: Assessment and Treatment

November 5, 2019 updated by: Sarah Michiels, Universiteit Antwerpen

The Effect of Conservative Treatment of Temporomandibular Disorders on Somatic Tinnitus

TMD treatment, based on state of the art knowledge derived from clinical studies will be applied in patients with tinnitus and TMD. When this approach proves to be useful for the treatment of tinnitus, it offers a new therapeutic option for patients with tinnitus. To understand how TMD treatment works for patients with tinnitus, we will analyse mediating factors, i.e. factors that contribute to the therapeutic effect. To help clinicians in their clinical process we will identify prognostic indicators, i.e. factors that predict a positive or negative outcome of TMD treatment. This can provide a helpful tool in clinical practice.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
120

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
    • Antwerpen
      • Edegem, Antwerpen, Belgium
        • Universitair Ziekenhuis Antwerpen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients will be included when suffering from somatic tinnitus, attributed to TMD, which has been stable for at least 3 months.
  • Tinnitus Functional Index score between 25 and 90

Exclusion Criteria:

  • clear otological or neurological causes of the tinnitus such as Menière's disease, severe depression (diagnosed by a psychologist), progressive middle ear pathology, intracranial pathology
  • traumatic cervical spine or temporomandibular injury in the past 6 months
  • tumours
  • previous surgery in the orofacial area
  • in case physical therapy treatment directed to the orofacial area is contra-indicated
  • if the patient received TMD treatment in the past 2 months
  • drug intake that can affect the outcome measures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Direct treatment
Patients receive the TMD treatment immediately
Other: TMD treatment: physiotherapy and/or occlusal splints
The patient will receive the most appropriate TMD treatment, based on current literature.
Experimental: Delayed treatment
No intervention in the first 9 weeks of the study. Afterwards, the patients receive the same treatment as the other group
Other: TMD treatment: physiotherapy and/or occlusal splints
The patient will receive the most appropriate TMD treatment, based on current literature.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Tinnitus Questionnaire
Time Frame: Baseline, 9 weeks, 18 weeks, 27 weeks
Questionnaire to measure the change in tinnitus related distress
Baseline, 9 weeks, 18 weeks, 27 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Tinnitus Functional Index
Time Frame: Baseline, 9 weeks, 18 weeks, 27 weeks
Questionnaire to measure the change in tinnitus severity
Baseline, 9 weeks, 18 weeks, 27 weeks
Hyperacusis Questionnaire
Time Frame: Baseline
Questionnaire to measure the presence of hyperacusis
Baseline
Visual analogue scale for tinnitus loudness
Time Frame: Baseline, 9 weeks, 18 weeks, 27 weeks
Scale to measure the change in average tinnitus loudness
Baseline, 9 weeks, 18 weeks, 27 weeks
TMD pain screener
Time Frame: Baseline, 9 weeks, 18 weeks, 27 weeks
Questionnaire to assess the presence of and change in temporomandibular disorders(TMD) symptoms
Baseline, 9 weeks, 18 weeks, 27 weeks
Hospital anxiety and depression scale
Time Frame: Baseline
Questionnaire to measure the presence of anxiety and/or depression
Baseline
Specific anamnestic questions
Time Frame: Baseline
pre-defined list of questions on duration of the tinnitus complaints, modulation, bruxism,...
Baseline
Static investigation of the temporomandibular joint
Time Frame: Baseline, 9 weeks, 18 weeks, 27 weeks
evaluation of change in isometric contraction of jaw muscles
Baseline, 9 weeks, 18 weeks, 27 weeks
Dynamic investigation of the temporomandibular joint
Time Frame: Baseline, 9 weeks, 18 weeks, 27 weeks
evaluation of change in isotonic contraction of jaw muscles
Baseline, 9 weeks, 18 weeks, 27 weeks
Pain pressure threshold
Time Frame: Baseline, 9 weeks, 18 weeks, 27 weeks
measurement of change in pain pressure thresholds on masseter, temporalis, temporomandibular joint, sternocleidomastoideus, tibialis anterior
Baseline, 9 weeks, 18 weeks, 27 weeks
Mouth opening
Time Frame: Baseline, 9 weeks, 18 weeks, 27 weeks
change in mouth opening measured in cm with a ruler
Baseline, 9 weeks, 18 weeks, 27 weeks
Pain on palpation of masseter, temporalis and temporomandibular joint
Time Frame: Baseline, 9 weeks, 18 weeks, 27 weeks
change in recognisable pain on palpation, measured on numerical rating scale
Baseline, 9 weeks, 18 weeks, 27 weeks
Tinnitus Analysis
Time Frame: Baseline
analysis of the tinnitus type, pitch and loudness
Baseline
Speech in noise test
Time Frame: Baseline, 9 weeks, 18 weeks, 27 weeks
analysis of the change in understanding spoken words in a noisy situation
Baseline, 9 weeks, 18 weeks, 27 weeks
Pure tone audiometry
Time Frame: Baseline
evaluation of possible hearing problems
Baseline
Auditory evoked potentials measurement
Time Frame: Baseline, 18 weeks
change in EEG during listening tasks
Baseline, 18 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Universiteit Antwerpen

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
University Hospital, Antwerp
Fonds voor Wetenschappelijk onderzoek Vlaanderen

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 27, 2017

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 30, 2019

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 5, 2019

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 19, 2017

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 3, 2017

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 6, 2017

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 6, 2019

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 5, 2019

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • T001916N

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tinnitus, Subjective

Clinical Trials on TMD treatment: physiotherapy and/or occlusal splints

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings